Stayble Therapeutics (STABL) Q4 2024 earnings summary

Executive summary

• Achieved positive phase 1b results for STA363, demonstrating safety and significant disc volume reduction versus placebo; no serious adverse events reported.

• European Patent Office issued "Intention to Grant" for STA363, strengthening IP position until at least 2040.

• Intensified partnering activities with multiple interested pharmaceutical companies; full TO2 warrant exercise raised SEK 2.64 million for continued operations.

• Scientific abstracts accepted for presentation at major international conferences, enhancing visibility and credibility.

Financial highlights

• Operating costs for 2024 were SEK 13,183k, down from SEK 24,101k in 2023.

• EBIT for 2024 was SEK -12,794k, improved from SEK -23,954k year-over-year.

• Net result for 2024 was SEK -12,418k, compared to SEK -23,737k in 2023.

• Q4 2024 operating costs were SEK 3,208k (Q4 2023: SEK 6,595k); EBIT SEK -3,205k (Q4 2023: SEK -6,457k).

• Cash and cash equivalents at year-end were SEK 2,195k, down from SEK 14,079k at end of 2023.

Outlook and guidance

• Management sees strong potential for a partnership or licensing deal for STA363 in 2025, supported by positive clinical data and active discussions.

• Raised capital from TO2 warrants will fund ongoing partnership negotiations and phase 2b preparations.